Circular RNA startup launches with $100M

February 24, 2021 – Barnes — who was also previously the chief scientific officer of Intellia Therapeutics — is referring to ex vivo cell therapy, a laborious and cost-intensive process by which cells are removed from a patient’s body, manipulated such that they can deliver treatments, then injected back in.